| INTRODUC TI ON
Invasive candidiasis and aspergillosis are serious opportunistic infections associated with significant morbidity and mortality. 1, 2 Invasive candidiasis is a prevalent nosocomial infection, ranked fourth highest among bloodstream infections in the US alone. 3 Invasive aspergillosis is relatively less common overall but highly prevalent among immunocompromised patients. With growing complexity in the treatment of underlying diseases and use of immunosuppressive therapies, there is increasing need for safe, efficacious antifungal treatment that can be safely coadministered in such patients at risk for invasive fungal infections.
Rezafungin is a novel echinocandin distinguished by its long-acting pharmacokinetics (half-life > 130 hours) and stability that support high plasma drug exposures and longer dosing intervals. [4] [5] [6] [7] [8] In vitro, rezafungin demonstrates similar activity to that of current echinocandins against Candida and Aspergillus spp., as well as activity against resistant strains, including azole-resistant
Aspergillus spp. and subsets of echinocandin-resistant Candida auris
and Candida glabrata. [9] [10] [11] [12] Recent studies have evaluated pharmacokinetic/pharmacodynamic (PK/PD) factors relating to rezafungin efficacy. 11, [13] [14] [15] The PK/PD index of AUC/MIC for rezafungin correlated well with efficacy and, compared with other echinocandins, rezafungin had lower PK/PD target exposures against Candida spp., including strains with resistance or reduced susceptibility to echinocandins. 11 While C max also predicted rezafungin efficacy, AUC was selected as it is more reliably measured. 16 Nevertheless, C max is an important index as shown in dose-fractionation and PK/PD target attainment analyses that demonstrated how rezafungin activity is driven by both the extent and the shape of drug exposure.
In effect, a single dose of rezafungin resulted in higher levels of drug exposure early in therapy and greater fungicidal activity compared with repeated daily dosing. 14 Rezafungin also demonstrated extensive distribution to tissue and penetration at the site of infection, as compared with micafungin in an intra-abdominal abscess candidiasis mouse model. 15 A series of in vivo studies using a mouse model of disseminated candidiasis were conducted to further evaluate rezafungin efficacy:
at extended intervals post-infection, against azole-resistant Candida albicans, and when antifungal treatment was delayed. Additionally, a neutropenic mouse model of disseminated aspergillosis was used to study the effect of a single rezafungin dose on survival, following a previous study in a similar mouse model that showed comparable survival rates among rezafungin-and amphotericin B-treated mice following 5 days of treatment. Discussion of results from these in vivo studies will consider the relationship between PK-PD determinants of antifungal efficacy, as observed for rezafungin.
Portions of these results were presented at ASM Microbe 2016
and Advances Against Aspergillosis 2016.
| MATERIAL AND ME THODS

| Drug, chemical reagents, and other materials
Rezafungin (RZF; Cidara Therapeutics, Inc) and anidulafungin (ANF;
Molcan, Toronto, Canada) were dissolved in 10% dimethyl sulfoxide (DMSO)/1% polysorbate (Tween) 20 in 0.9% saline. Fluconazole (FLU;
Sigma-Aldrich) was dissolved in water for injection. Amphotericin B (AmB; Sigma-Aldrich) was dissolved in 0.9% saline. The dosing volume was 10 mL/kg for all groups.
| Test systems used
Minimal inhibitory concentration (MIC) and minimal effective con- 
| Experimental design
For all experiments in the invasive candidiasis model, mice were im- 
| Assessment of efficacy against Candida at increasing intervals
Rezafungin 1, 3, 10, or 30 mg/kg IP and FLU 20 mg/kg orally (PO) was administered 2 hours post-infection (C. albicans R303;
1.41 × 10 3 CFU), and kidney CFU/g at 120 and 168 hours post-infection in the rezafungin groups were compared with those of the FLU group at 24 hours and of the vehicle control group at 72 hours.
| Assessment of efficacy against azoleresistant Candida albicans (R357)
ATCC R357; 1.41 × 10 5 CFU). Kidney fungal counts at 48 and 72 hours post-infection in the treated and control groups were compared. 
| Assessment of efficacy against
| Compliance with design and statistical analysis requirements
Group comparisons for each infection model were made between groups of equal size (n = 5, invasive candidiasis model; n = 10, invasive aspergillosis model). Randomization and blinding were not part of the study design of these in vivo experiments, and bias due to their absence was considered to be minimal. 
| Data analysis and statistical procedures
| Efficacy against azole-resistant Candida albicans (R357)
Treatment with rezafungin at all tested doses resulted in ≥ 99% re- 
| In vivo efficacy: mouse model of disseminated Aspergillosis
In mice infected with A. fumigatus ATCC 13073 and treated with a one-time dose of rezafungin 2 mg/kg, the 10-day survival rates were significantly higher (100%) than in the vehicle group (20%). Survival rates following a one-time dose of rezafungin 2 mg/kg (either as a single dose or fractionated dose given twice daily for 5 days), administered IV or IP, were comparable to those of AmB given 3 mg/ kg ( Figure 3 ).
| D ISCUSS I ON
Rezafungin is a novel echinocandin that was designed for greater stability and for pharmacokinetics that would enable more flexible dosing regimens than those of existing echinocandins, while retaining the general activity and safety of the class. 18 Truly, since its discovery, extensive research has demonstrated the enhanced stability and safety, in vitro activity, and distinctive pharmacokinetics of rezafungin. [6] [7] [8] [19] [20] [21] Studies also have evaluated the efficacy of rezafungin in vivo and with respect to pharmacometrics-ie, the pharmacokinetic and pharmacodynamic relationships of exposure and response that predict efficacy. 13 The current series of experiments expand on previous studies (Table 1 ) and, to the extent that in vivo findings may translate to clinical outcomes, provide greater insight on the potential of rezafungin in the treatment of invasive fungal infections.
F I G U R E 2 Efficacy with delayed treatment against
Significant in vivo efficacy (≥99%, 2-log reduction in CFU/g) was previously observed following rezafungin treatment at up to 72 hours post-infection in a neutropenic mouse model of disseminated candidiasis. 6, 22 The present experiment using a similar infection model showed that one dose of rezafungin was efficacious at up to 192 hours The experiment of rezafungin treatment 24 hours after infection also builds upon previous evaluations of antifungal efficacy, as well as of drug exposure as a determinant of efficacy. 11 The efficacy of rezafungin despite later treatment initiation may be attributable in part to the front-loaded pattern of rezafungin drug exposure. 13, 14 Briefly, the concentration-dependent fungicidal action and high plasma drug exposure of rezafungin lend themselves to rapid, extensive killing early in the course of treatment when fungal burden is greatest. The benefit to efficacy from front-loaded patterns of exposure has been substantiated with both single and intermittent doses of rezafungin 14 compared with once-daily administration of currently approved echinocandins. 25 In target attainment analyses based on Phase 1 data, single and once-weekly doses of rezafungin achieved high (≥90% and 100%, respectively) probabilities of target attainment against contemporary strains of C. albicans and Candida glabrata. 16 The PK/ PD profile of rezafungin, namely its high plasma drug exposure and wide safety margin, may also be relevant to preventing resistance, as postulated by the mutant selection window hypothesis and mutant prevention concentration (MPC; the minimal concentration of a drug that inhibits development of mutant subpopulations) determined for rezafungin. 15 While prevention of resistance remains hypothetical, PK/PD determinants of efficacy clearly favor the ability to readily achieve and safely maintain high levels of drug in plasma.
The in vivo efficacy of rezafungin reported herein against azole-resistant C. albicans (R357) expands the database on rezafungin against less susceptible and resistant Candida spp., 11, 12, 15 including the inherently multidrug-resistant and difficult-to-treat Candida auris (Table 1) . 9, 10, [26] [27] [28] [29] 
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